Exploring new treatment options for polycystic ovary syndrome: Review of a novel antidiabetic agent SGLT2 inhibitor

作     者：Jelena Marinkovic-Radosevic Maja Cigrovski Berkovic Egon Kruezi Ines Bilic-Curcic Anna Mrzljak 

作者机构：Department of EndocrinologyDiabetes and MetabolismSisters of Charity Clinical Hospital CentreZagreb 10000Croatia Department of EndocrinologyDiabetesMetabolism and Clinical PharmacologyClinical Hospital DubravaZagreb 10000Croatia Department of Kinesiological Anthropology and MethodologyFaculty of KinesiologyUniversity of ZagrebZagreb 10000Croatia Department of Gynecology and ObstetricsSisters of Charity Clinical Hospital CentreZagreb 10000Croatia Department of PharmacologyFaculty of MedicineUniversity of J.J.Strossmayer OsijekOsijek 31000Croatia Clinical Hospital Center OsijekOsijek 31000Croatia School of MedicineUniversity of ZagrebZagreb 10000Croatia Department of Gastroenterology and HepatologyUniversity Hospital Centre ZagrebZagreb 10000Croatia 

出 版 物：《World Journal of Diabetes》 (世界糖尿病杂志（英文版）（电子版）)

年 卷 期：2021年第12卷第7期

页      面：932-938页

核心收录：

学科分类：1002[医学-临床医学] 100211[医学-妇产科学] 10[医学] 

主　　题：Polycystic ovary syndrome Sodium-glucose co-transporter-2 inhibitors Metabolic risk Cardiovascular risk Metabolic syndrome Insulin resistance Obesity Type 2 diabetes mellitus Dyslipidemia 

摘      要：Polycystic ovary syndrome(PCOS)is the most common endocrinopathy in women of reproductive age associated with long-term metabolic and cardiovascular consequences.A plethora of symptoms and their severity differentiate on an individual level,giving the syndrome numerous *** to menstrual cycle abnormalities,women suffer from irregular menstrual bleeding,difficulty in conception,and ***,the risk of pregnancy complications such as gestational diabetes mellitus,hypertensive disorders of pregnancy,and preterm birth are higher in women with PCOS than in the general ***,women with PCOS have comorbidities such as dyslipidemia,obesity,glucose intolerance or diabetes type 2,non-alcoholic fatty liver disease,and metabolic syndrome,which all influence the treatment *** insulinsensitizing agents,although good for some of the metabolic derangements,do not offer long-term cardiovascular benefits;therefore,new treatment options are of paramount ***-glucose co-transporter-2(SGLT-2)inhibitors,a new class of antidiabetic agents with beneficial cardiovascular,bodyweight,and antihyperglycemic effects,although not approved for the treatment of PCOS,might be an attractive therapeutic addition in the PCOS ***,recent studies with SGLT-2 inhibitors showed promising improvements in anthropometric parameters and body composition in patients with *** is important to further explore the SGLT-2 inhibitors potential as an early therapeutic option because of the PCOS-related risk of metabolic,reproductive,and psychological consequences.